Phase II Study of Panitumumab, Nab-paclitaxel, and Carboplatin for Patients With Primary Inflammatory Breast Cancer (IBC) Without HER2 Overexpression
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 May 2018
At a glance
- Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Panitumumab (Primary) ; Cyclophosphamide; Epirubicin; Fluorouracil
- Indications Inflammatory breast cancer
- Focus Therapeutic Use
- 30 Apr 2018 Planned End Date changed from 1 Nov 2018 to 1 Nov 2021.
- 30 Apr 2018 Planned primary completion date changed from 1 Nov 2018 to 1 Nov 2021.
- 27 Apr 2017 Planned primary completion date changed from 1 Nov 2017 to 1 Nov 2018.